Nymox Pharmaceutical Corp. (NYMX) just announced that results from its Phase 2 prostate cancer study demonstrated statistically significant better outcomes at up to 2.8 years for NX-1207 treated patients compared to controls.
Nymox Pharmaceutical has suddenly spiked to the upside on increased volume and is now up 0.64 at $1.63. The stock is challenging the upper end of a 2 1/2 week range.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.